160 related articles for article (PubMed ID: 12417606)
21. Nonmyeloablative allogeneic hematopoietic stem cell transplantation in 26 cases of hematological malignancies.
Su LP; Xu LR; Jiang B; Ye F; Zhu QJ; Lu YJ; Cui YE; Zhu L; Zhang L; Ma XL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Aug; 14(4):773-7. PubMed ID: 16928319
[TBL] [Abstract][Full Text] [Related]
22. Health economic evidence for the use of molecular biomarker tests in hematological malignancies: A systematic review.
Vu M; Degeling K; Thompson ER; Blombery P; Westerman D; IJzerman MJ
Eur J Haematol; 2022 Jun; 108(6):469-485. PubMed ID: 35158410
[TBL] [Abstract][Full Text] [Related]
23. [Hematological malignancies].
Usui N
Gan To Kagaku Ryoho; 2007 Mar; 34(3):358-66. PubMed ID: 17353625
[TBL] [Abstract][Full Text] [Related]
24. Reduced-intensity conditioned allogeneic haematopoietic stem cell transplantation results in durable disease-free and overall survival in patients with poor prognosis myeloid and lymphoid malignancies: eighty-month follow-up.
Patil S; Spencer A; Schwarer A; Lewis I; Hertzberg M; Avery S; Wei A; Noutsos T; Paul E; Taouk Y; Muirhead J
Bone Marrow Transplant; 2010 Jul; 45(7):1154-60. PubMed ID: 19898502
[TBL] [Abstract][Full Text] [Related]
25. BCR-ABL-positive acute myeloid leukemia: a new entity? Analysis of clinical and molecular features.
Neuendorff NR; Burmeister T; Dörken B; Westermann J
Ann Hematol; 2016 Aug; 95(8):1211-21. PubMed ID: 27297971
[TBL] [Abstract][Full Text] [Related]
26. Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting.
Hou JZ; Ye JC; Pu JJ; Liu H; Ding W; Zheng H; Liu D
J Hematol Oncol; 2021 Apr; 14(1):66. PubMed ID: 33879198
[TBL] [Abstract][Full Text] [Related]
27. [DNA diagnosis in hematological malignancies].
Nara N
Rinsho Byori; 2001 Mar; Suppl 115():37-44. PubMed ID: 11391935
[TBL] [Abstract][Full Text] [Related]
28. [Prognostic molecular marker and molecular targeted-therapy in pediatric malignancies].
Hayashi Y
Gan To Kagaku Ryoho; 2007 Feb; 34(2):194-202. PubMed ID: 17301526
[TBL] [Abstract][Full Text] [Related]
29. Programmed death-1 immune checkpoint blockade in the treatment of hematological malignancies.
Tsirigotis P; Savani BN; Nagler A
Ann Med; 2016 Sep; 48(6):428-439. PubMed ID: 27224873
[TBL] [Abstract][Full Text] [Related]
30. Adoptive immunotherapy for hematological malignancies: Current status and new insights in chimeric antigen receptor T cells.
Allegra A; Innao V; Gerace D; Vaddinelli D; Musolino C
Blood Cells Mol Dis; 2016 Nov; 62():49-63. PubMed ID: 27865176
[TBL] [Abstract][Full Text] [Related]
31. [Modern therapy of hematologic malignancies].
Trnĕný M
Cas Lek Cesk; 2001 Nov; 140(23):711-6. PubMed ID: 11787232
[TBL] [Abstract][Full Text] [Related]
32. Hematologic Malignancies Discovered on Investigation of Breast Abnormalities.
Alsadi A; Lin D; Alnajar H; Brickman A; Martyn C; Gattuso P
South Med J; 2017 Oct; 110(10):614-620. PubMed ID: 28973700
[TBL] [Abstract][Full Text] [Related]
33. CAR therapy for hematological cancers: can success seen in the treatment of B-cell acute lymphoblastic leukemia be applied to other hematological malignancies?
Pegram HJ; Smith EL; Rafiq S; Brentjens RJ
Immunotherapy; 2015; 7(5):545-61. PubMed ID: 26065479
[TBL] [Abstract][Full Text] [Related]
34. [Bcr-Abl inhibition as molecular therapy approach in chronic myeloid leukemia].
Buchdunger E
Med Klin (Munich); 2002 Jan; 97 Suppl 1():2-6. PubMed ID: 11831067
[TBL] [Abstract][Full Text] [Related]
35. [The minimal residual disease (MRD) in hematological malignancies].
Yokota S; Okamoto T
Gan To Kagaku Ryoho; 2001 Jun; 28(6):762-8. PubMed ID: 11432342
[TBL] [Abstract][Full Text] [Related]
36. Changes in therapy for solid tumors: potential for overcoming drug resistance in vivo with molecular targeting agents.
Kim R; Toge T
Surg Today; 2004; 34(4):293-303. PubMed ID: 15052442
[TBL] [Abstract][Full Text] [Related]
37. Hematological cancer in 2011: New therapeutic targets and treatment strategies.
Cramer P; Hallek M
Nat Rev Clin Oncol; 2012 Jan; 9(2):72-4. PubMed ID: 22231754
[TBL] [Abstract][Full Text] [Related]
38. [Necessity of Genetic Examination in Treatment for Hematological Malignancies].
Kiyoi H
Rinsho Byori; 2015 Mar; 63(3):369-76. PubMed ID: 26524860
[TBL] [Abstract][Full Text] [Related]
39. Non-AIDS-defining hematological malignancies in HIV-infected patients: an epidemiological study in Japan.
Hagiwara S; Yotsumoto M; Odawara T; Ajisawa A; Uehira T; Nagai H; Tanuma J; Okada S
AIDS; 2013 Jan; 27(2):279-83. PubMed ID: 23014520
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic potential of a reduced-intensity preparative regimen for allogeneic transplantation with cladribine, busulfan, and antithymocyte globulin against advanced/refractory acute leukemia/lymphoma.
Saito T; Kanda Y; Kami M; Kato K; Shoji N; Kanai S; Ohnishi T; Kawano Y; Nakai K; Ogasawara T; Matsubara H; Makimoto A; Tanosaki R; Tobinai K; Wakasugi H; Takaue Y; Mineishi S
Clin Cancer Res; 2002 Apr; 8(4):1014-20. PubMed ID: 11948108
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
